After an inspection of Hospira’s medical device quality systems in Lake Forest, Ill., the FDA issued a list of 10 objectionable conditions in a Form 483. So far in 2013, the company has sent out 11 device notifications, including recalls and corrections.
Hospira’s Clayton, N.C., facility recently resumed producing propofol, and plans to re-launch the drug shortly.
More Articles on Anesthesia:
ASA Opposes Proposed Changes to Opioid Labels by FDA
Dr. Shawn Crook Joins Bothwell Regional Health Center
Hamilton Medical Anesthesia Ventilator Contains Software Problems
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
